116 related articles for article (PubMed ID: 25692521)
21. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
23. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
[TBL] [Abstract][Full Text] [Related]
24. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Stein DM; Dutton RP; Kramer ME; Scalea TM
J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic laboratory for bleeding disorders ensures efficient management of haemorrhagic disorders.
Riddell A; Chuansumrit A; El-Ekiaby M; Nair SC
Haemophilia; 2016 Jul; 22 Suppl 5():90-5. PubMed ID: 27405683
[TBL] [Abstract][Full Text] [Related]
26. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
27. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
[TBL] [Abstract][Full Text] [Related]
29. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
30. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
31. Outbreak of dengue fever in Karachi 2006: a clinical perspective.
Riaz MM; Mumtaz K; Khan MS; Patel J; Tariq M; Hilal H; Siddiqui SA; Shezad F
J Pak Med Assoc; 2009 Jun; 59(6):339-44. PubMed ID: 19534364
[TBL] [Abstract][Full Text] [Related]
32. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost-utility analysis.
Saiyarsarai P; Robabpour Derakhshan A; Khedmati J; Eshghi P; Seyedifar M
Medicine (Baltimore); 2021 Oct; 100(40):e27303. PubMed ID: 34622828
[TBL] [Abstract][Full Text] [Related]
33. Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Jen H; Shew S
J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942
[TBL] [Abstract][Full Text] [Related]
34. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of recombinant activated factor VIIa for 18 patients with severe bleeding].
Liu ZL; Yang L; Liu MM; Bai O; Cui JW; Li PT; Li W
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):409-11. PubMed ID: 22781803
[TBL] [Abstract][Full Text] [Related]
36. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly.
Duchesne JC; Mathew KA; Marr AB; Pinsky MR; Barbeau JM; McSwain NE
Am Surg; 2008 Dec; 74(12):1159-65. PubMed ID: 19097529
[TBL] [Abstract][Full Text] [Related]
37. Antidotes to haemorrhage: recombinant factor VIIa.
Kessler CM
Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom.
Morris S; Ridley S; Munro V; Christensen MC
Anaesthesia; 2007 Jan; 62(1):43-52. PubMed ID: 17156226
[TBL] [Abstract][Full Text] [Related]
39. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
Flower O; Phillips LE; Cameron P; Gunn K; Dunkley S; Watts A; Rajbhandari D
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):207-15. PubMed ID: 20182351
[TBL] [Abstract][Full Text] [Related]
40. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
